Breast cancer causes and treatment: where are we going wrong?

被引:7
|
作者
Seymour, Colin B. [1 ]
Mothersill, Carmel [1 ]
机构
[1] McMaster Univ, Med Phys & Appl Radiat Sci Dept, Hamilton, ON L8S 2C1, Canada
来源
BREAST CANCER-TARGETS AND THERAPY | 2013年 / 5卷
关键词
breast cancer; causes; treatment; questioning paradigms;
D O I
10.2147/BCTT.S44399
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This discussion paper seeks to provoke thoughts about cancer research in general, and why breast cancer in particular is not yet "curable". It asks the question - are we looking at the disease in the right way? Should we regard cancer as a progressive state, which is part of aging? Should we tailor treatment to "reset" the system or slow progression rather than try using toxic and aggressive therapy to kill every cancer cell (and sometimes also the patient)? The thesis is presented that we need to revisit our fundamental beliefs about the disease and then ask why we cling to beliefs that clearly are no longer valid. The paper also questions the role of ethics boards in hampering research and discusses the concept that breast cancer is an industry with vested interests involving profiteering by preventive, diagnostic, and therapeutic players. Finally, the paper suggests some ways forward based on emerging concepts in system biology and epigenetics.
引用
收藏
页码:111 / 119
页数:9
相关论文
共 50 条
  • [31] Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?
    Turnbull, Samantha
    West, Emma J.
    Scott, Karen J.
    Appleton, Elizabeth
    Melcher, Alan
    Ralph, Christy
    VIRUSES-BASEL, 2015, 7 (12): : 6291 - 6312
  • [32] Hypothyroidism in Context: Where We’ve Been and Where We’re Going
    Luca Chiovato
    Flavia Magri
    Allan Carlé
    Advances in Therapy, 2019, 36 : 47 - 58
  • [33] Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'
    Ingle, James N.
    BREAST CANCER RESEARCH, 2008, 10 (Suppl 4)
  • [34] Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'
    James N Ingle
    Breast Cancer Research, 10
  • [35] Steroid metabolism in breast cancer: Where are we and what are we missing?
    Africander, Donita
    Storbeck, Karl-Heinz
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2018, 466 : 86 - 97
  • [36] Ethnicity and breast cancer in the UK: Where are we now?
    Gathani, Toral
    Chaudhry, Anushka
    Chagla, Leena
    Chopra, Sharat
    Copson, Ellen
    Purushotham, Arnie
    Vidya, Raghavan
    Cutress, Ramsey
    EJSO, 2021, 47 (12): : 2978 - 2981
  • [37] Targeted therapies in breast cancer: Where are we now?
    Di Cosimo, Serena
    Baselga, Jose
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2781 - 2790
  • [38] Prevention of posttraumatic osteoarthritis at the time of injury: Where are we now, and where are we going?
    Mason, Deborah
    Englund, Martin
    Watt, Fiona E.
    JOURNAL OF ORTHOPAEDIC RESEARCH, 2021, 39 (06) : 1152 - 1163
  • [39] Fatty liver and nonalcoholic steatohepatitis - Where do we stand and where are we going?
    Lonardo, A
    DIGESTIVE DISEASES, 1999, 17 (02) : 80 - 89
  • [40] The efficacy and acceptability of psychological interventions for depression: where we are now and where we are going
    Hollon, Steven. D.
    EPIDEMIOLOGY AND PSYCHIATRIC SCIENCES, 2016, 25 (04) : 295 - 300